Table 2.
Clinical and pathological features of 2,728 patients in GPSM cohort from Table 1 of Thompson et al [1] that are used to define patients for the CK model.
| Parameter (units) | Value | |
|---|---|---|
| Pathological Gleason score (%) | ||
| ≤ 5 | 5.2 | |
| 6 | 61.1 | |
| 7 | 27.8 | |
| 8 – 10 | 5.9 | |
| Maximum tumor dimension (%) | Inferred spherical tumor volume | |
| 0 – 1.4 cm | 33.3 | 0 – 1.4 cc |
| 1.5 – 2.4 cm | 30.4 | 1.8 – 7.2 cc |
| 2.5 – 2.9 cm | 11.4 | 8.2 – 12.7 cc |
| ≥ 3 cm | 24.9 | ≥ 14.1 cc |
| Pathological tumor stage (%) | ||
| T2 | 82.4 | |
| T3a | 9.1 | |
| T3b/4 | 6.5 | |
| Tx N+ | 2.0 | |
| GPSM score (%) | ||
| < 6 | 1.5 | |
| 6 | 13.9 | |
| 7 | 31.1 | |
| 8 | 17.6 | |
| 9 | 13.7 | |
| 10 | 10.0 | |
| 11 | 5.0 | |
| 12 | 3.2 | |
| ≥ 13 | 4.0 | |
| Positive margins (%) | 30 | |
| PSA (μg/L) | 0.2 – 144 | |
| Median | 6.4 | |
| Median PSADT (yr) | 1.26 | |